Fenofibrate

This product is a blood lipid regulating drug of clofibric acid derivatives. It reduces blood low-density lipoprotein, cholesterol and triglycerides by inhibiting the production of very low-density lipoprotein and triglycerides and increasing their catabolism at the same time; it also increases the production of apolipoprotein A1 and A11, thereby increasing high-density lipoprotein. This product also has the effect of reducing blood uric acid in normal people and patients with hyperuricemia. Animal experiments have shown that fenofibrate is teratogenic and carcinogenic.

Fenofibrate glue.

This product is an orange-red capsule containing a white or off-white suspension-type semi-solid substance.

It is used to treat hypercholesterolemia (type IIa), endogenous hypertriglyceridemia, simple type (type IV) and mixed type (type IIb and III) in adults who have not responded well to dietary control therapy, especially when blood cholesterol continues to rise after dietary control or there are other concurrent risk factors.

1. This drug can be taken for a long time in combination with diet control, and the efficacy should be monitored regularly. 2. Oral administration, 0.2g at a time, once a day, taken with meals. 3. When cholesterol levels are normal, it is recommended to reduce the dose.

1. When used in combination with other fibrates, muscle dysfunction (diffuse pain, tenderness, muscle weakness) and rare severe rhabdomyolysis have been reported. Most of these adverse reactions are reversible after discontinuation of the drug (see the warning section for details). 2. Other less common, moderate adverse reactions have also been reported: gastric or intestinal digestive dysfunction, such as dyspepsia; elevated transaminases (see the precautions section for details); occasional allergic skin reactions, such as rash, itching, urticaria, or photosensitivity reactions have been reported. In some cases, even after discontinuation of the drug for several months, erythema, papules, rashes and eczema will still occur when the skin is exposed to sunlight or artificial ultraviolet rays. There are currently no long-term comparative studies to fully evaluate adverse reactions, especially the risk of gallstones.

This drug is contraindicated in the following situations: those who are allergic to fenofibrate; those with impaired liver function; those with impaired renal function (see the Warning section); those who are known to experience phototoxicity or photosensitivity when using fenofibrate or structurally similar drugs, especially ketoprofen, during treatment; combined use with other fibrates (see the Drug Interactions section); children; this drug is generally not recommended for use with HMG-COA reductase inhibitors (see the Drug Interactions section) and should not be used during breastfeeding (see the Pregnancy and Lactation section). Patients who are allergic to this product and its ingredients are contraindicated.

Precautions for children: Children are prohibited from using it. Precautions for pregnancy and lactation: Animal test results show no teratogenic effects. So far, clinical teratogenicity and embryotoxicity have not been found, but the follow-up of fenofibrate use during pregnancy is not sufficient to rule out any danger, so it should be prohibited for pregnant women in general. Fibrates are not used in pregnant women, except when dietary control cannot effectively reduce high triglycerides (>10g/L) and increases the risk of acute pancreatitis in the mother. There is currently no data on the entry of fenofibrate into the mother. However, it is prohibited during lactation. Precautions for the elderly: It is recommended to use the normal adult dose, and the dose can be reduced if there is renal impairment.

Concomitant use of other fibrates with the following drugs is prohibited: Increased incidence of adverse reactions such as rhabdomyolysis and pharmacodynamic antagonism between the two molecules. Drugs not recommended for concomitant use HMG-COA reductase inhibitors: Increased incidence of muscle adverse reactions such as rhabdomyolysis. Use drugs with caution.

seal.

0.2 g

24 months

Zhejiang Aisheng Pharmaceutical Co., Ltd.

• Founded in:

  1995-12-25

• Address:

  No. 8, Second Street, Hangzhou Economic and Technological Development Zone, Zhejiang Province

• Tax NO.:

  91330101609136936H

• Registered Funds:

  43.029824 yuan

• Website:

  Log in to view

• Email:

  Log in to view